New drug tested to stop Early-Stage blood cancer before it worsens
NCT ID NCT05055063
Summary
This early-phase trial is testing the safety and best dose of the drug belantamab mafodotin for people with high-risk smoldering multiple myeloma, a condition where abnormal blood cells are present but haven't yet caused major symptoms. The study will enroll 30 participants to find the maximum safe dose and see if the drug shows signs of controlling the disease. Researchers will monitor how patients respond and track side effects to determine if larger studies are warranted.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.